Ji Luo, Ph.D.
Laboratory of Cancer Biology and Genetics
Building 37, Room 4054B
Bethesda, MD 20892
Our long-term goal is to understand the mechanisms of tumorigenesis and identify new therapeutic strategies for cancer treatment. In particular, we focus on understanding the biology of Ras mutant cancer and identifying new treatment approaches for Ras tumors. Research in the lab focuses on the follow areas:
Synthetic Lethal Partners of the KRAS Oncogene
We have previously conducted RNAi screens to identify synthetic lethal partners of the KRAS oncogene (Luo et al., Cell, 2009). Our current effort is focused on elucidating the molecular mechanisms by which these genes support Ras-driven oncogenesis. In particular, we are studying how RNA splicing factors (Weng et al., PNAS, 2012) and SUMO ligases (Yu et al., submitted) supports the oncogenic activity of KRAS and how these pathways might be exploited for therapeutic gain. Investigation of other candidate synthetic lethal partners of KRAS is also underway. Our analysis indicates that cancer cells exhibit non-oncogene addiction to a broad network of genes that act to alleviate oncogenic stress and enable cancer cell survival. Therapeutic approaches that exploit non-oncogene addiction should provide new avenues to target cancer cells. We are studying bioactive molecules and developing small-molecule inhibitors that target non-oncogene addiction to assess their potentials in cancer therapy.
Genetic Dissection of Cancer Using RNAi and CRISPR
We are developing new RNAi and CRISPR tools to enable genetic screens with improved penetrance and reduced off-target effects. Recently, we have developed new RNAi tools for a combinatorial siRNA screen to identify optimal drug target combinations against KRAS mutant cancer cells (Yuan et al., Cancer Discovery, 2014). We are also developing new vector systems that allow the introduction of complex genetic alternations in cells to better model the genetic complexities seen in human cancer.
We are investigating new therapeutic modalities against Ras cancers. We have developed a new chemical screening platform for discovering compounds that can destabilize KRAS protein (Carver et al., PLOS One, 2014). As part of the CCR Major Opportunities Initiative, we have developed a pharmacological synthetic lethal screen to identify, from a collection of FDA-approved and clinical-stage compounds, drug combinations that show selective toxicity in KRAS mutant cells. Our goal is to translate these findings into early stage clinical trials within a few years.
Positions: To inquire about potential postdoctoral and postbaccalaureate openings, please e-mail a cover letter and C.V. to Dr. Luo.
Read A, Gao S, Batchelor E, Luo J. Flexible CRISPR library construction using parallel oligonucleotide retrieval. Nucleic Acids Res. 2017;45(11):e101.
Yu B, Swatkoski S, Holly A, Lee LC, Giroux V, Lee CS, Hsu D, Smith JL, Yuen G, Yue J, Ann DK, Simpson RM, Creighton CJ, Figg WD, Gucek M, Luo J. Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9. Proc Natl Acad Sci U S A. 2015;112(14):E1724-33.
Yuan TL, Fellmann C, Lee CS, Ritchie CD, Thapar V, Lee LC, Hsu DJ, Grace D, Carver JO, Zuber J, Luo J, McCormick F, Lowe SW. Development of siRNA payloads to target KRAS-mutant cancer. Cancer Discov. 2014;4(10):1182-1197.
Weng MT, Lee JH, Wei SC, Li Q, Shahamatdar S, Hsu D, Schetter AJ, Swatkoski S, Mannan P, Garfield S, Gucek M, Kim MK, Annunziata CM, Creighton CJ, Emanuele MJ, Harris CC, Sheu JC, Giaccone G, Luo J. Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells. Proc Natl Acad Sci U S A. 2012;109(52):E3659-67.
Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, Wong KK, Elledge SJ. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell. 2009;137(5):835-48.
Related Scientific Focus Areas
Genetics and Genomics
This page was last updated on June 15th, 2017